Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
Given possible lack of benefit findings in subset analysis of Monarch 3, would you still use Abemaciclib in a postmenopausal woman with high-risk ER+ breast cancer?
Related Questions
How do you reconcile data from the PATINA trial and DESTINY-Breast09 with respect to CDK4/6 inhibitor maintenance in metastatic ER+ HER2+ breast cancer?
Is the currently available data from INAVO sufficient to adopt this as a new standard of care for all patients or are you awaiting overall survival and/or PROs?
What supportive care measures do you prioritize to manage or prevent toxicity in patients receiving Dato-DXd?
Do you recommend using a ctDNA assay for a patient with HER2+ metastatic breast cancer in a continued CR to guide decision about whether to stop anti therapy?
How do the findings from the INAVO120 trial influence your decision-making process for selecting subsequent lines of therapy in patients who have relapsed after adjuvant CDK4/6 inhibition?
What are your top takeaways in Breast Cancer from ASCO 2025?
For patients with ER-negative HER2-ultralow breast cancer, how and when would you incorporate T-DXd?
What are your top takeaways in Radiation Oncology from SABCS 2024?
Is there benefit of cold-cap use while patient is on sacituzumab-govitecan?
In a patient with metastatic PIK3CA-mutant, HR-positive, HER2-low breast cancer who is intolerant to capivasertib, would you consider treatment with alpelisib plus fulvestrant or with Enhertu?
